Abiopharma

Press Release: Sanofi launches 2026 global employee stock purchase plan

WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

111, Inc. Announces First Quarter 2026 Unaudited Financial Results

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Alvotech leggur inn að nýju umsóknir um markaðsleyfi í Bandaríkjunum fyrir hliðstæður við Simponi, Simponi Aria og Eylea

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Expro Strengthens Longstanding Partnership With Deployment of Solus™ Technology in the Gulf of America

Register of shareholders, changes and capital status – exercise of warrants for shares (unlisted) by employees

Shelf offering report for the issuance of BONDS C, according to the shelf prospectus dated 29.8.23, orders: 4.6.26